RE:RE:RE:CovisafeRob to a user on another forum
We now own 50% of Torion which is where the Covisafe technology will reside. Our agreement was to develop the technology and move it to commercial viability which is what we are doing now. Pilot testing moves it closer to achieving regulatory approval which allows us to sell the product in the future. There are other partners that brought the IP to the table who receive the other 50% of Torion. That IP resides in Torion. RapsAlot wrote: No mention of Orpheus in phase 3 ony Therma Bright. Rob's email to a shareholder on another forum speaks on that.
During Phase 2, Therma's and Orpheus' partnership with various clinical institutions will focus on clinical validation of the test prototype in up to 250 clinical samples. After Phase 2, Therma can decide to advance to Phase 3 only upon success with Phases 1 and 2. Phase 3 will include regulatory enabling studies where the Parties expect to apply for EUA approvals during Phase 3 including commercialization activities.